HC Wainwright Issues Positive Forecast for Enlivex Therapeutics (NASDAQ:ENLV) Stock Price

Enlivex Therapeutics (NASDAQ:ENLV) had its price objective hoisted by investment analysts at HC Wainwright from $6.00 to $7.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a research report on Monday, March 3rd.

Enlivex Therapeutics Trading Down 4.1 %

Shares of NASDAQ ENLV opened at $1.05 on Monday. The company’s 50-day moving average price is $1.10 and its 200 day moving average price is $1.24. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.59. The stock has a market cap of $22.37 million, a price-to-earnings ratio of -1.07 and a beta of 1.11.

Institutional Trading of Enlivex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Securities LLC purchased a new stake in Enlivex Therapeutics during the 4th quarter worth about $26,000. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 112.6% in the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after purchasing an additional 84,203 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Enlivex Therapeutics during the 4th quarter worth about $742,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.